UK markets close in 4 hours 8 minutes

M1 Kliniken AG (MKLNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
11.730.00 (0.00%)
At close: 11:51AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.73
Open11.73
BidN/A x N/A
AskN/A x N/A
Day's range11.73 - 11.73
52-week range11.04 - 11.93
Volume1,647
Avg. volume34
Market cap219.148M
Beta (5Y monthly)0.71
PE ratio (TTM)26.90
EPS (TTM)0.44
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    M1 Kliniken AG successfully held its Annual General Meeting 2021

    DGAP-News: M1 Kliniken AG / Key word(s): AGM/EGM/Miscellaneous16.07.2021 / 09:24 The issuer is solely responsible for the content of this announcement.M1 Kliniken AG successfully held its Annual General Meeting 2021Berlin, 16 July 2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) successfully held its Annual General Meeting 2021 on 14 July 2021.After the Corona-related restrictions of the previous year, the Management Board is confident about the development of the company in the current financial year

  • EQS Group

    M1 Kliniken AG publishes figures for the 1st quarter of 2021: successful start to 2021 with significant increase in revenues and earnings in both business segments

    DGAP-News: M1 Kliniken AG / Key word(s): Quarterly / Interim Statement/Miscellaneous01.06.2021 / 08:30 The issuer is solely responsible for the content of this announcement.M1 Kliniken AG publishes figures for the 1st quarter of 2021: successful start to 2021 with significant increase in revenues and earnings in both business segments Group turnover rises to almost EUR 81 million (EUR 23 million in Q1-2020) Group EBITDA amounts to EUR 4.0 million (previous year: EUR 1.4 million); EBIT amounts to EUR 2.6 million (previous year: EUR 0.5 million) Beauty: After restrained treatment figures at the beginning of the quarter, significant increase compared to the previous year at the end of the quarter Trade: Continuation of operational optimisations - sales/result still without effects of COVID antigen rapid testsBerlin, 1.06.2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) announces figures for the first quarter of 2021. According to these figures, the consolidated group revenue of the M1 Group in the first quarter of the financial year 2021 rose by approx. 250% year-on-year to just under EUR 81 million (previous year: EUR 23 million). Of this, HAEMATO AG (without M1 Aesthetics), which was not yet consolidated in the same period of the previous year, accounted for sales of a good EUR 59 million.In the beauty segment, the start into the new year was very restrained due to Corona, with treatment figures that were significantly below the previous year (-20%). Towards the end of the quarter, this picture turned around, so that M1 was able to reach and further increase its historical peak daily sales several times in a row. In Q1-2021 as a whole, just over 81 thousand treatments were performed compared to 73 thousand treatments in the same quarter last year. Turnover in the Beauty segment rose to EUR 13 million after EUR 11.5 million in the previous year. The development in the international locations was particularly pleasing, with treatment numbers increasing from just under 4 thousand (Q1-2020) to over 7 thousand (Q1-2021). Since 12 April 2021, the two locations in the UK have also been reopened, which achieved very pleasing occupancy rates right from the start.In the trading segment, the ongoing operational optimisation of the business activities of HAEMATO AG is particularly noteworthy, which was able to report a further increase in turnover in the past quarter compared to the previous year. HAEMATO AG was able to significantly improve its profitability. These figures do not yet include the effects of the antigen rapid test approved by the Federal Institute for Drugs and Medical Devices (BfArM) on 23 March 2021 in accordance with Section 11 (1) of the German Medical Devices Act (MPG), the sales of which will significantly positively strengthen the sales and earnings of HAEMATO AG from April.EBITDA of M1 Kliniken AG in Q1-2021 totalled EUR 4.0 million (previous year: EUR 1.4 million), EBIT amounted to EUR 2.6 million (previous year: EUR 0.5 million). The previous year was marked by the first foothills of the Corona pandemic with the closure of all sites from 23 March 2020. In addition, development and start-up losses of the international sites still burdened the earnings statement in the previous year with a negative EBIT contribution of around EUR 1.0 million, which was limited to a negative EBIT of around EUR 0.2 million in Q1-2021."We are convinced that we will be able to successfully continue the course M1 Kliniken AG has embarked upon also in the further course of financial year 2021. By the end of May 2021 four new specialist centres had already been opened in the German market, and at least two more specialist centres are to follow by the end of the year. The search for new locations has also been resumed in the foreign markets, so that the planned number of 50 locations by the end of 2021 is within reach," says the CEO of M1 Kliniken AG, Dr. Walter von Horstig.Due to the currently ongoing Corona pandemic, M1 Kliniken AG will again make use of the option to invite shareholders to the Company's Annual General Meeting scheduled for 14 July 2021 with an abbreviated notice period of 21 days.About M1 Kliniken AGM1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 40 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia. With its shareholding in HAEMATO AG, which has existed since mid-2020, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field.Contact:M1 Kliniken AGDr. Walter von Horstig, Management BoardGrünauer Straße 512557 BerlinT: +49 (0)30 347 47 44 14M: ir@m1-kliniken.de01.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: M1 Kliniken AG Grünauer Straße 5 12557 Berlin Germany Phone: +49 (0)30 347 47 44 14 Fax: +49 (0)30 347 47 44 17 E-mail: ir@m1-kliniken.de Internet: https://www.m1-kliniken.de ISIN: DE000A0STSQ8 WKN: A0STSQ Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1202882 End of News DGAP News Service

  • EQS Group

    M1 Kliniken AG publishes preliminary figures for the 2020 financial year: revenue rises to € 160 million; net profit for the year amounts to € 7.4 million.

    DGAP-News: M1 Kliniken AG / Key word(s): Preliminary Results/Miscellaneous27.04.2021 / 11:00 The issuer is solely responsible for the content of this announcement.M1 Kliniken AG publishes preliminary figures for the 2020 financial year: revenue rises to € 160 million; net profit for the year amounts to € 7.4 million - Group turnover rises by more than 100 % to 159.6 million euros- Consolidated net income falls by 24 % to 7.4 million euros due to the pandemic- Outlook for 2021: restart of expansion and promotion of private label businessBerlin, 27 April 2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the financial year 2020. In the past financial year, the M1 Group was able to maintain its market leadership in Germany in the field of aesthetic medicine and - despite considerable burdens due to pandemic-related closures of clinics - generated a clearly positive operating result. In addition, the acquisition of Haemato AG laid the foundation for the development and expansion of the private label business.In the 2020 financial year, the M1 Group was able to increase consolidated group sales by more than 100% to 159.6 million euros (previous year: 77.2 million euros). This includes sales of Haemato AG for the period Aug. - Dec. 2020 in the amount of 102.8 million euros. The closure of the clinic and practice operations in spring 2020 locked two full months of revenue and the occupancy rates of the specialist centres were also "below potential" in Q4 2020 due to the pandemic. However, revenue in the "Beauty" segment fell by only 7% year-on-year to €37.4 million (previous year: €40.3 million). Including the international locations, the group performed almost 270,000 treatments.The operating profit 2020 (EBIT) amounted to 4.4 million euros (previous year 7.9 million euros). In this context, M1 recorded an operating loss of 1.9 million euros in its foreign beauty subsidiaries - due to very long lock-down periods (especially UK and Australia) and the activities in most foreign subsidiaries still in the early stages. Haemato AG achieved an operating result (EBIT) of 1.6 million euros for the full year 2020.The financial result fell from €4.8 million (2019) to €4.4 million. This includes income of 3.6 million euros from the initial consolidation of Haemato AG.Earnings before taxes fell from 12.7 million euros to 8.8 million euros. Consolidated net income for the year fell to 7.4 million euros (previous year: 9.7 million euros). Earnings per share amounted to 0.37 euros (previous year: 0.56 euros).At 61%, the equity ratio remains at a very high level (previous year: 74 %). Due to the full consolidation of Haemato AG as of 31 December 2020, higher bank liabilities are included and reduce the equity ratio compared to the previous year. Cash flow amounted to 12.9 million euros.According to current planning, the company expects to restart its growth course in the beauty segment for the full year 2021, whereby the specific timing of the expansion will be largely determined by the development of the Corona pandemic. To date, three new specialist centres have already been opened in Germany (Kiel, Erfurt, Freiburg), and two more openings are being prepared until mid 2021. Abroad, all specialist centres are open to the public again since 12 April 2021. Activities to open further international specialist centres have been resumed. By the end of 2024, a total of 100 specialist centres for aesthetic medicine are targetted. The first interim goal is a total of 50 specialist centres by the end of 2021.The subsidiary Haemato AG intends to continue its economic recovery course in 2021. In March 2021, the company received a special approval in accordance with § 11 para. 1 MPG from the Federal Institute for Drugs and Medical Devices (BfArM) for the antigen rapid test for self-testing of laypersons. The current Corona strategy of the Federal Government and the Federal States, which has made the submission of negative Covid tests obligatory for many areas of public life and the economy, currently leads us to expect a high demand for these rapid tests.At the beginning of the Corona pandemic in the first half of 2020, M1 Kliniken AG signed a KfW-backed entrepreneurial loan to secure the Group's liquidity. In this context the distribution profits to the shareholders is blocked. The Board of Management will therefore propose to the Annual General Meeting to carry forward the balance sheet profit in full to new account.The Annual Report 2020 of M1 Kliniken AG will be published on 27 May 2021.About M1 Kliniken AGM1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik for plastic und aesthetic surgery in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia.After the acquisition of Haemato AG in 2020 and the bundeling of all trade and product development activities M1 is now pushing forward the private label product business. Contact:M1 Kliniken AGDr. Walter von Horstig, Management BoardGrünauer Straße 512557 BerlinT: +49 (0)30 347 47 44 14M: ir@m1-kliniken.de27.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: M1 Kliniken AG Grünauer Straße 5 12557 Berlin Germany Phone: +49 (0)30 347 47 44 14 Fax: +49 (0)30 347 47 44 17 E-mail: ir@m1-kliniken.de Internet: https://www.m1-kliniken.de ISIN: DE000A0STSQ8 WKN: A0STSQ Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1188461 End of News DGAP News Service